Cross Timbers Royalty Trust
Change company Symbol lookup
Select an option...
CRT Cross Timbers Royalty Trust
ABBV Abbvie Inc
DD Dupont De Nemours Inc
NRXPW NRX Pharmaceuticals Equity Warrant Exp 24 May 2026 *W EXP 05/24/2026
SAH Sonic Automotive Inc
PCRX Pacira Biosciences Inc
ONFO Onfolio Holdings Inc
LSPRU Larkspur Health Acquisition Corp
BKKT Bakkt Holdings Inc
PDI PIMCO Dynamic Income Fund
Go

Energy : Oil, Gas & Consumable Fuels | Small Cap Blend
Company profile

Cross Timbers Royalty Trust (the Trust) is an express trust. The net profits interests are the principal asset of the Trust. The Trust receives net profits income from the net profit interests generally on the last business day of each month. The net profits interests comprise of approximately 90% net profits interests, which are carved from producing royalty and overriding royalty interest properties in Texas, Oklahoma and New Mexico, and 11.11% nonparticipating royalty interests in nonproducing properties located primarily in Texas and Oklahoma; and the approximately 75% net profits interests which are carved from working interests in four properties in Texas and three properties in Oklahoma. Its underlying royalties, underlying nonproducing royalties and underlying working interest properties are owned by XTO Energy. The underlying properties include approximately 2,900 producing properties in Texas, Oklahoma and New Mexico.

Closing Price
$22.12
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
54,473

10-day average volume:
37,670
54,473

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences

8:00 am ET September 8, 2022 (Globe Newswire) Print

EQNX::TICKER_START (TSX:REUN),(NASDAQ:REUN), EQNX::TICKER_END Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or ("the Company"), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate in two upcoming investor conferences in September 2022.

H.C. Wainwright 24 Annual Global Investment Conference

Reunion's management team will present at a virtual fireside chat at the H.C. Wainwright 24 Annual Global Investment Conference, taking place on September 12-14, 2022. A recording of the fireside chat will be available on demand from 7:00 a.m. Eastern Time on Monday, September 12, 2022 for 90 days through the following link: https://journey.ct.events/view/715a2d59-3d1f-40a4-9314-0f1ac6b4902a.

Jefferies Innovation in Mental Health Summit

The Reunion management team will participate in a fireside chat at the Jefferies Innovation in Mental Health Summit, taking place in New York City on September 22, 2022. The event will be webcast and is accessible on Reunion's investor relations website for 90 days.

Institutional investors interested in scheduling a meeting with Reunion's management team, or for more information on the conferences, please contact KCSA Strategic Communications at Reunion@kcsa.com.

About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)

Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company's lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.

Learn more at https://investors.reunionneuro.com, and https://www.reunionneuro.com.

Follow us on Twitter and Instagram: @reunionneuro.

To be added to the Reunion Neuroscience email list, please email Reunion@kcsa.com with "REUN" in the subject line.

Cautionary Note Regarding Forward-Looking Information

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC's website at www.sec.gov.

Neither Toronto Stock Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:

Reunion Neuroscience:

Joseph del Moral

Chairman & CEO

(416) 219-1050

joseph@reunionneuro.com

Media contacts:

Caitlin Kasunich

KCSA Strategic Communications

(212) 896-1241

reunion@kcsa.com

Investor contacts:

Phil Carlson / Sophia Bashford

KCSA Strategic Communications

(646) 573-0776 / (929) 246-7307

reunion@kcsa.com

SOURCE Reunion Neuroscience Inc.

https://ml.globenewswire.com/media/0446e058-6399-48c6-a279-a8c703bf1bd7/small/logo-low-res-jpg.JPG

https://ml.globenewswire.com/media/0446e058-6399-48c6-a279-a8c703bf1bd7/small/logo-low-res-jpg.JPG

comtex tracking

COMTEX_414001284/2010/2022-09-08T08:00:06

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.